Experts from RSC and Antihypertensive League created a brochure for medical practitioners that integrates the most used scales and lists of cardiological risks.

25.08.20152235
Experts from RSC and Antihypertensive League created a brochure for medical practitioners that integrates the most used scales and lists of cardiological risks.

Atrial fibrillation risk increases with higher free thyroxine levels

25.08.20151480
Higher free thyroxine levels within the normal range increased the risk for atrial fibrillation, especially among younger adults, according to recent study findings published in The Journal of Clinical Endocrinology & Metabolism.

Edoxaban prevents VTE better than enoxaparin after total hip arthroplasty

24.08.20151489
Oral edoxaban showed superior to subcutaneous enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty, according to findings published in Thrombosis Journal.

Organic compound produced by intestinal bacteria linked to atherosclerosis, mortality

21.08.20151631
Trimethylamine-N-oxide, an organic compound produced by intestinal bacteria, was associated with coronary atherosclerosis burden and mortality among patients with chronic kidney disease in a recent study.

NAFLD may be linked to heart failure

20.08.20151469
In a cross-sectional analysis, researchers found that nonalcoholic fatty liver disease was independently associated with subclinical myocardial remodeling and dysfunction, which may indicate an association with heart failure.

TWILIGHT trial will evaluate ticagrelor without aspirin in patients with coronary stents

19.08.20152238
The Icahn School of Medicine at Mount Sinai announced the initiation of a trial that will evaluate the safety and efficacy of ticagrelor monotherapy compared with ticagrelor plus aspirin in patients implanted with a coronary stent.

APPRAISE-2: Apixaban does not affect outcomes, may increase bleeding after ACS

18.08.20151460
In patients with ACS, apixaban did not improve outcomes and was associated with increased bleeding, regardless of background concomitant antiplatelet therapy, according to new findings from the APPRAISE-2 trial.
Данный сайт и вся информация на нём предназначена для медицинских работников. Продолжая просмотр, вы соглашаетесь и подтверждаете, что являетесь медицинским работником.